VivoSim Labs, INC. VIVS
VivoSim Labs, INC. (Nasdaq: VIVS) is a life-science services company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| FXR314 (sold to Eli Lilly March 2025; VivoSim retains milestone rights only) | inflammatory bowel disease / ulcerative colitis | small molecule | Phase 2 |
| NAMkind liver / intestinal tissue toxicology services | drug-induced liver injury / intestinal tox screening | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.